Lipid-induced insulin resistance is prevented in lean and obese myotubes by AICAR treatment.
The molecular mechanisms of obesity-associated insulin resistance are becoming increasingly clear, and the effects of various lipid molecules, such as diacylglycerol and ceramide, on the insulin signal are being actively explored. To better understand the divergent response to lipid exposure between lean and obese, we incubated primary human muscle cells from lean [body mass index (BMI) <25 kg/m(2)] and morbidly obese (BMI >40 kg/m(2)) subjects with the saturated fatty acid palmitate. Additionally, given that AMPK-activating drugs are widely prescribed for their insulin-sensitizing effects, we sought to determine whether 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside (AICAR)-stimulated AMPK activation could prevent or reverse the deleterious effects of lipid on insulin signaling. We found that a 1-h palmitate incubation in lean myotubes reduced (P < 0.05) insulin-stimulated phosphoprotein kinase B (Akt), Akt substrate 160 (AS160), and inhibitory factor kappaBalpha (IkappaBalpha) mass, all of which were prevented with AICAR inclusion. With a longer incubation, we observed that myotubes from morbidly obese individuals appear to be largely resistant to the detrimental effects of 16 h lipid exposure as was evident, in contrast to the lean, by the absence of a reduction in insulin-stimulated insulin receptor substrate (IRS)-1 Tyr phosphorylation, phospho-Akt, and phospho-AS160 (P < 0.05). Furthermore, 16 h lipid exposure significantly reduced IkappaBalpha levels and increased phosphorylation of c-Jun NH(2)-terminal kinase (JNK) and IRS1-Ser(312) in lean myotubes only (P < 0.05). Despite a divergent response to lipid between lean and obese myotubes, AICAR inclusion improved insulin signaling in all myotubes. These findings suggest an important role for regular exercise in addition to offering a potential mechanism of action for oral AMPK-activating agents, such as thiazolidinediones and metformin.
Bikman
Benjamin T
BT
The Metabolic Institute for the Study of Diabetes and Obesity, East Carolina University, Greenville, North Carolina 27834, USA.
Zheng
Donghai
D
Reed
Melissa A
MA
Hickner
Robert C
RC
Houmard
Joseph A
JA
Dohm
G Lynis
GL
D000620:Aminoimidazole Carboxamide / Q000378:metabolism / Q000494:pharmacology*; D015992:Body Mass Index; D005227:Fatty Acids / Q000378:metabolism; D005260:Female; D006801:Humans; D007093:Imidazoles; D007328:Insulin / Q000378:metabolism / Q000494:pharmacology; D055504:Insulin Receptor Substrate Proteins / Q000378:metabolism; D007333:Insulin Resistance; D008055:Lipids / Q000494:pharmacology*; D018485:Muscle Fibers, Skeletal / Q000378:metabolism*; D009765:Obesity / Q000378:metabolism*; D010168:Palmitates / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology
D005227:Fatty Acids; D007093:Imidazoles; D007328:Insulin; D055504:Insulin Receptor Substrate Proteins; D008055:Lipids; D010168:Palmitates; D010750:Phosphoproteins; D000620:Aminoimidazole Carboxamide; C098330:4-aminoimidazole; D051057:Proto-Oncogene Proteins c-akt
Nat Med. 2005 Feb;11(2):183-90
15685173
Diabetes. 2008 Nov;57(11):2958-66
18728234
Biochem Soc Trans. 2003 Feb;31(Pt 1):220-3
12546689
Eur Cytokine Netw. 2006 Mar;17(1):4-12
16613757
Int J Obes Relat Metab Disord. 2001 Oct;25(10):1407-15
11673759
Curr Opin Lipidol. 2008 Feb;19(1):11-5
18196981
Diabetes. 2002 Oct;51(10):2959-63
12351433
Biochem Biophys Res Commun. 2006 Mar 10;341(2):507-14
16427608
Nature. 2002 Nov 21;420(6913):333-6
12447443
J Biol Chem. 2002 Dec 27;277(52):50230-6
12006582
J Neurosci. 2004 Jan 14;24(2):479-87
14724246
Diabetes. 2005 Jan;54(1):41-50
15616009
Am J Physiol Cell Physiol. 2005 Oct;289(4):C794-801
15888549
J Biol Chem. 2004 Jun 4;279(23):23942-52
15028733
J Biol Chem. 2004 Aug 27;279(35):36608-15
15220355
J Clin Invest. 2001 Aug;108(3):437-46
11489937
J Clin Invest. 2001 Oct;108(8):1167-74
11602624
Biochem Biophys Res Commun. 2004 Nov 26;324(4):1204-9
15504342
J Cell Physiol. 2008 Nov;217(2):478-85
18561258
Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E726-32
12488242
Diabetes. 2006 Jul;55(7):2051-8
16804075
N Engl J Med. 1990 Jan 25;322(4):223-8
2403659
Cardiovasc Res. 2009 Jan 1;81(1):133-9
18703532
Antioxid Redox Signal. 2006 Mar-Apr;8(3-4):478-86
16677091
J Clin Endocrinol Metab. 2001 Mar;86(3):1306-12
11238525
Cell Metab. 2008 Apr;7(4):348-56
18396141
J Appl Physiol (1985). 2004 Jan;96(1):101-6
12972442
J Biol Chem. 2003 Mar 21;278(12):10297-303
12525490
Hypertension. 2004 May;43(5):924-31
15007038
Mol Cell Endocrinol. 2008 Sep 24;292(1-2):36-41
18606210
Diabetes. 2007 Feb;56(2):414-23
17259386
J Biol Chem. 2002 Jan 11;277(2):1531-7
11606564
Ann N Y Acad Sci. 2002 Jun;967:146-57
12079844
Diabetes. 2004 Dec;53(12):3258-66
15561958
J Clin Invest. 2007 Jun;117(6):1679-89
17510710
Diabetes. 1999 Jun;48(6):1270-4
10342815
J Appl Physiol (1985). 2001 Sep;91(3):1017-28
11509493
Science. 2001 Aug 31;293(5535):1673-7
11533494
J Physiol. 2006 Dec 15;577(Pt 3):997-1007
17008371
J Cell Physiol. 2008 May;215(2):392-400
17960559
J Biol Chem. 2004 Oct 1;279(40):41294-301
15252018
Hypertension. 2006 Jun;47(6):1183-8
16636195
Diabetes. 2002 Jan;51(1):7-18
11756317
Diabetes. 2006 Aug;55(8):2277-85
16873691
Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E485-93
17003244
Med Sci Sports Exerc. 1982;14(1):101-2
7070249
J Biol Chem. 2004 Apr 23;279(17):17070-8
14764603
J Clin Endocrinol Metab. 2008 Dec;93(12):4656-63
18765510
Nat Med. 2005 Feb;11(2):191-8
15685170
Cell Metab. 2006 Dec;4(6):465-74
17141630
Nutr Rev. 2007 Jun;65(6 Pt 2):S39-46
17605313
J Clin Invest. 1988 Aug;82(2):486-94
3403714
Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E175-81
16464908
Diabetes. 2007 Aug;56(8):1960-8
17620421